In vivo treatment of Helicobacter pylori infection with liposomal linolenic acid reduces colonization and ameliorates inflammation

Soracha Thamphiwatana,Weiwei Gao,Marygorret Obonyo,Liangfang Zhang

DOI: https://doi.org/10.1073/pnas.1418230111

IF: 11.1

2014-11-24

Proceedings of the National Academy of Sciences

Abstract:Significance The use of a liposomal formulation of linolenic acid to kill Helicobacter pylori bacteria in the stomach represents a powerful treatment option for H. pylori infection, as well as its associated gastroduodenal diseases. Because the therapeutic agent is a natural compound found in common vegetable oils, such treatment is expected to be cost-effective compared with the existing antibiotic-based anti- H. pylori therapeutics. More important, the excellent antimicrobial efficacy, marked by significantly reduced in vivo bacterial colonization and inflammation, is achieved through rapid fusion of the nanoformulation with bacterial membrane, a mechanism known to overcome bacterial drug resistance. Similar therapeutic approaches can be developed to treat various types other bacterial infections.